Page 639 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

599
26. METHOTREXA TE ETDÉRIVES ANT7FOLIQUES
PIPER J.R. et al., Synthesis and antifolate activity of 5-methyl-5-deaza analogues of ami-
nopteridin, methotrexate, folic acid, and N'O-methylfolic acid, J. Med. Chem., 1986,
29, 1080-1087.
BASSENDINE M.F. et al., Induction of remission in hepatocellular carcinoma with a new
thymidilate synthetase inhibitor, CB 3717, a phase Il study, J. Hepatol., 1987, 4, 349-
346.
JONES T.R. et al., Quinazoline antifolated inhibiting thymidylate synthetase : 2-deasa-
mino derivatives with enhanced solubility and potency, J. Med. Chem, 1989, 32, 847-
852.
MARSHAM P.R. et al., Quinazoline antifolate thymidylate synthetase inhibitors : nitrogen,
oxygen, sulfur, and chlorine substituents in the C2 position, J. Med. Chem., 1989, 32,
569-575.
HUGHES L., Quinazoline antifolate thymidylate synthase inhibitors, J. Med. Chem.,
1990, 33, 3060-3067.
MARSHAM P., Quinazoline antifolate thymidylate synthase inhibitors, J. Med. Chem.,
1991, 34, 1594-1605.
BISSET G., Syntheses and thymidylate synthase inhibitory activity of ICI D-1694 and
other quinazoline antifolates, J. Med. Chem., 1992, 35, 859-866.
WESTERHOF G.R. et al., Carrier and receptors-mediated transport of folate antagonists
targeting folate-dependant enzymes : correlates of molecular-structure and biological
activity, Mol. Pharmacol., 1995, 48, 459-471.
MEAD G.M. Raltitrexed, a new drug for advanced colorectal cancer, Lancet, 1996, 1568-
1569.
TOUROUTOGLOU N., Thymidylate synthase inhibitors, Clin. CancerRes., 1996, 2, 227-
243.
Raltitrexed - Tomudex, Drugs of the Future, 1997, 22, 449-450.
BEALE P. Metabolism, excretion and pharmacokinetics of a single dose of 14C-ralti-
trexed in cancer patients, Cancer Chemother. Pharmacol., 1998, 42, 71-76.
BLACKLEDGE G., New developments ln cancer treatment with the novel thymidylate
synthase inhibitor Raltitrexed, Br. J. Cancer, 1998, 77, suppl 2, 29-37.
GUNASEKARA N., Raltitrexed, a review of its pharrnacological properties and clinical
efficacy, Drugs, 1998, 55, 423-435.

PRODUITS EN DÉVELOPPEMENT
Pyritrexim, Drugs of the Future, 1985, 10, 108 et 1998, 23, 234-235.
TAYLOR E. et al., A dideazatetrahydrofolate analogue lacking a chiral C-6, inhibitor of
TS. J. Med. Chem., 1992, 35, 4450-4454.
Lometrexol, Drugs of the Future, 1993, 18, 121 et 1997, 22, 189-90.
Édatrexate, Drugs of the Future, 1997, 22, 1036-1037.
Trimetrexate, Drugs of the Future, 1997, 22, 582.
KOKURYO Y., Synthesis and evaluation of novel fluorinated methotrexate derivates, J.
Med. Chem., 1997, 40, 3280-3291.
SHIH C. et al., LY 231514, a pyrrolo(2,3-d]pyrimidine which inhibits multiple folate-requi-
ring enzymes, Cancer Res., 1997, 57, 1116-1123.
OUELLET D. et al., Population pharmacokinetics of pemetrexed disodium in patients
with cancer, Cancer Chemother. Pharmacol., 2000, 46, 227-234.